A Phase 1/2 interventional study of feladilimab and Tremelimumab in Neoplasms, sponsored by GlaxoSmithKline. Completed at 8 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-28.
Sponsored by GlaxoSmithKline · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate if the combination of GSK3359609 and tremelimumab is safe and tolerable (Part 1) and provides significant survival benefit to subjects with relapsed/refractory (R/R) Head and Neck Squamous Cell Carcinomas (HNSCC) to warrant further clinical investigation (Part 2). Part 1 (dose escalation) will enroll subjects with advanced, selected solid tumors. Subjects will receive escalating doses of GSK3359609 and tremelimumab in combination in Part 1. Part 2 is randomized expansion and will enroll subjects with R/R HNSCC who have disease progression after receiving at least 1 platinum-based chemotherapy and at least 1 anti-programmed death receptor protein-1 (PD-1)/anti-programmed death-ligand 1 (PD-L1) therapy, whether in combination or separately. In Part 2, subjects will be randomized in a ratio of 2:1 to receive either GSK3359609 in combination with tremelimumab at the recommended Phase 2 dose or investigators choice of a single-agent standard of care (SOC) therapy including paclitaxel, docetaxel or cetuximab. The total duration of subjects in the study will be approximately 4 years.
10,832 studies on the registry are indexed under Neoplasms; 2,324 are open to participants now.
This study's enrollment of 26 is below the median of 60 across 7,712 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In Part 1, subjects with advanced selected solid tumors will be enrolled. Subjects will be administered escalating doses of feladilimab and tremelimumab in combination. feladilimab will be administered every 3 weeks and tremelimumab will be administered every 3 weeks for 6 doses and every 12 weeks thereafter.
Drug: feladilimab · Drug: Tremelimumab
In Part 2, subjects with R/R HNSCC who have disease progression after receiving at least one platinum-based chemotherapy and at least one anti-PD-1/PD-L1 will be enrolled. Subjects will be administered feladilimab in combination with tremelimumab at recommended Phase 2 dose as determined from Part 1.
Drug: feladilimab · Drug: Tremelimumab
In Part 2, subjects with R/R HNSCC who have disease progression after receiving at least one platinum-based chemotherapy and at least one anti-PD-1/PD-L1 will be enrolled. Subjects will be administered a single agent SOC therapy of either paclitaxel, docetaxel or cetuximab as per the investigators choice.
Drug: Docetaxel · Drug: Paclitaxel · Drug: Cetuximab
feladilimab is humanized anti-ICOS agonist immunoglobulin G (IgG) 4 monoclonal antibody (mAb), which will be administered as an intravenous (IV) infusion once every 3 weeks.
Tremelimumab is humanized anti-CTLA-4 IgG2 mAb, which will be administered as an IV infusion once every 3 weeks for 6 doses, thereafter once every 12 weeks .
Docetaxel is a microtubule stabilizer which will be administered as an IV infusion once every 3 weeks at a dose of 75 milligrams per meter square (mg/m\^2).
Paclitaxel is a microtubule stabilizer which will be administered as an IV infusion once weekly at a dose of 80 mg/m\^2.
Cetuximab is a recombinant, human/mouse chimeric anti-estimated glomerular filtration rate (EGFR) mAb. Cetuximab will be administered at a loading dose of 400 mg/m\^2 followed by 250 mg/m\^2 once weekly.
Number of Participants With Dose Limiting Toxicities (DLTs)-Part 1
A DLT is considered by the investigator to be clinically relevant, attributed event within first 28 days of intervention meeting the following criteria of toxicity, Hematologic: Febrile neutropenia, Grade 4 neutropenia of greater than (\>) 7 days in duration or requiring Granulocyte- Colony stimulating factor (G-CSF), Grade 4 anemia and Grade 3 thrombocytopenia with bleeding or Grade 4 thrombocytopenia; Non-hematologic: Grade 4 toxicity, Grade 3 pneumonitis, any greater than or equal to (≥) Grade 2 pneumonitis that does not resolve to less than or equal to (≤ ) Grade 1 within 3 days of the initiation of maximal supportive care, Grade 3 toxicity that does not resolve to Grade 1 or baseline within 3 days despite optimal supportive care and any Grade 2 ocular toxicity requiring systemic steroids, or any ≥ Grade 3 ocular toxicity.
Time frame: Up to 28 days
Number of Participants With DLTs According to Severity-Part 1
The severity of all toxicities were graded using the National Cancer Institute- Common Toxicity Criteria for Adverse Events (NCI-CTCAE) version 5.0. Grade 1: Mild reaction; infusion interruption not indicated; intervention not indicated; Grade 2: Requires therapy or infusion interruption but responds promptly to symptomatic treatment or prophylactic medications indicated for ≤24 hours; Grade 3: Prolonged (i.e., not rapidly responsive to symptomatic medication and/or brief interruption of infusion) or recurrence of symptoms following initial improvement; hospitalization indicated for other clinical sequelae; Grade 4: Life-threatening; pressor or ventilatory support indicated; Grade 5: Death related to AE.
Time frame: Up to 28 days
Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESI)-Part 1
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is defined as any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent disability/incapacity; is a congenital anomaly/birth defect and important medical events may jeopardize the subject or may require medical or surgical intervention/SOC to prevent one of the other outcomes mentioned before. AESIs are defined as events of potential immunologic etiology, including immune related AEs.
Time frame: Up to 4 years
Number of Participant With AE/SAE/DLTs Leading to Dose Modifications/Delays/Withdrawals-Part 1
The number of participants with AE/SAE/DLTs leading to dose modifications/delays/withdrawals were summarized.
Time frame: Up to 4 years
Number of Participants With AEs, SAEs, AESIs According to Severity - Part 1
The severity of all toxicities were graded using the National Cancer Institute- Common Toxicity Criteria for Adverse Events (NCI-CTCAE) version 5.0. Grade 1: Mild reaction; infusion interruption not indicated; intervention not indicated; Grade 2: Requires therapy or infusion interruption but responds promptly to symptomatic treatment or prophylactic medications indicated for ≤24 hours; Grade 3: Prolonged (i.e., not rapidly responsive to symptomatic medication and/or brief interruption of infusion) or recurrence of symptoms following initial improvement; hospitalization indicated for other clinical sequelae; Grade 4: Life-threatening; pressor or ventilatory support indicated; Grade 5: Death related to AE.
Time frame: Up to 4 years
Number of Participants With Severe- AEs/SAEs/DLTs Leading to Dose Modifications/Delays/Withdrawals-Part 1
The number of participants with severe- AE/SAE/DLTs leading to dose modifications/delays/withdrawals were summarized.
Time frame: Up to 4 years
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)-Part 1
SBP and DBP were measured after 5 minutes of rest for the participant.
Time frame: Baseline (Day 1) and Week 4
Change From Baseline in Temperature-Part 1
Temperature was measured after 5 minutes of rest for the participant.
Time frame: Baseline (Day 1) and Week 4
Change From Baseline in Pulse Rate-Part 1
Pulse rate was measured after 5 minutes of rest for the participant.
Time frame: Baseline (Day 1) and Week 4
Change From Baseline in Respiratory Rate-Part 1
Respiratory rate was measured after 5 minutes of rest for the participant.
Time frame: Baseline (Day 1) and Week 4
Change From Baseline in Oxygen Saturation-Part 1
Oxygen saturation was measured using pulse oximeter after 5 minutes of rest for the participant.
Time frame: Baseline (Day 1) and Week 4
Number of Participants With Electrocardiogram (ECG) Findings
Single 12-lead ECG was obtained using an automated ECG machine. ECG findings were categorized as: normal, abnormal - clinically significant (CS), or abnormal - not clinically significant (NCS), as determined by the investigator.
Time frame: Baseline (Pre dose, Day 1) and up to 4 Years
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count-Part 1
Blood samples were collected to assess change from Baseline in neutrophil, lymphocyte, monocyte, eosinophil, basophil and platelet counts.
Time frame: Baseline (Day 1) and Week 4
Change From Baseline in Hemoglobin Level-Part 1
Blood samples were collected to assess change from baseline in hemoglobin level.
Time frame: Baseline (Day 1) and Week 4
Change From Baseline in Hematocrit Level-Part 1
Blood samples were collected to assess change from baseline in hematocrit level.
Time frame: Baseline (Day 1) and Week 4
Change From Baseline in Erythrocytes Count-Part 1
Blood samples were collected to assess change from baseline in Erythrocytes count.
Time frame: Baseline (Day 1) and Week 4
Change From Baseline in Albumin and Total Protein Levels-Part 1
Blood samples were collected to assess change from Baseline in albumin and total protein levels.
Time frame: Baseline (Day 1) and Week 4
Change From Baseline in Creatinine and Bilirubin Levels-Part 1
Blood samples were collected to assess change from baseline in creatinine and bilirubin levels.
Time frame: Baseline (Day 1) and Week 4
Change From Baseline in Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP), Lactate Dehydrogenase (LDH) Levels-Part 1
Blood samples were collected to assess change from baseline in ALT, AST ALP, LDH levels.
Time frame: Baseline (Day 1) and Week 4
Change From Baseline in Amylase and Lipase Levels-Part 1
Blood samples were collected to assess change from baseline in amylase and lipase levels.
Time frame: Baseline (Day 1) and week 4
Change From Baseline in Urea, Glucose, Potassium, Sodium and Calcium Levels-Part 1
Blood samples were collected to assess change in levels of urea, glucose, potassium, sodium and calcium from baseline.
Time frame: Baseline (Day 1) and Week 4
Change From Baseline in Specific Gravity of Urine-Part 1
Urine samples were collected to assess change from baseline in specific gravity of urine.
Time frame: Baseline (Day 1) and Week 4
Change From Baseline in Potential of Hydrogen (pH) of Urine-Part 1
Urine samples were collected to assess change from baseline in pH of urine.
Time frame: Baseline (Day 1) and Week 4
Number of Participants With Abnormal Urinalysis Parameters-Part 1
The dipstick test gives positive or negative results for protein, ketones, occult blood and glucose in urine. Positive test results were considered as abnormal. Number of participants with positive test results have been summarized.
Time frame: Week 4
Change From Baseline in Thyroid Stimulating Hormone (TSH) or Thyrotropin-Part 1
Blood samples were collected to assess change from Baseline in TSH.
Time frame: Baseline (Day 1) and Week 4
Change From Baseline in Free Triiodothyronine (T3)-Part 1
Blood samples were collected to assess change from Baseline in free T3.
Time frame: Baseline (Day 1) and Week 4
Change From Baseline in Free Thyroxine (T4)-Part 1
Blood samples were collected to assess change from baseline in free T4.
Time frame: Baseline (Day 1) and Week 4
Overall Survival-Part 2
For participants in Part 2, overall survival is defined as time from the date of randomization to the date of death due to any cause.
Time frame: Up to 4 years
Overall Response Rate-Part 1
Overall response rate is defined as percentage of participants with confirmed complete response (Disappearance of all target lesions. Any pathological lymph nodes \[whether target or non-target\] must have reduction in short axis to \<10 millimeter \[mm\]) or partial response (At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters) at any time as per response evaluation criteria in solid tumors (RECIST) version 1.1.
Time frame: Up to 4 years
Overall Response Rate-Part 2
Overall response rate is defined as percentage of participants with confirmed complete response (Disappearance of all target lesions. Any pathological lymph nodes \[whether target or non-target\] must have reduction in short axis to \<10 mm) or partial response (At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters) at any time as per RECIST version 1.1.
Time frame: Up to 4 years
Disease Control Rate-Part 1
Disease control rate is defined as percentage of subjects with confirmed complete response (Disappearance of all target lesions. Any pathological lymph nodes \[whether target or non-target\] must have reduction in short axis to \<10 mm) or partial response (At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters) or at least 18 weeks of stable disease (Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD) as per RECIST version 1.1.
Time frame: Up to 4 years
Disease Control Rate-Part 2
Disease control rate is defined as percentage of subjects with confirmed complete response (Disappearance of all target lesions. Any pathological lymph nodes \[whether target or non-target\] must have reduction in short axis to \<10 mm) or partial response (At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters) or at least 18 weeks of stable disease (Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD) as per RECIST version 1.1.
Time frame: Up to 4 years
Progression Free Survival-Part 2
For Part 2, progression free survival duration is defined as the time from the date of randomization to first documented evidence of disease progression (At least a 20% increase in the sum of diameters of target lesions and In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm) or death (regardless of cause of death), whichever comes first as per RECIST version 1.1.
Time frame: Up to 4 years
Time to Response-Part 2
Time to response is defined as the time from the first dose to the first documented evidence of complete response (Disappearance of all target lesions. Any pathological lymph nodes \[whether target or non-target\] must have reduction in short axis to \<10 mm) or partial response (At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters) for participants with a confirmed CR or PR as per RECIST version 1.1.
Time frame: Up to 4 years
Duration of Response-Part 2
Duration of response is defined as time from the first documented evidence of response until the first documented sign of disease progression or death among participants who achieve a response (CR \[Disappearance of all target lesions. Any pathological lymph nodes {whether target or non-target} must have reduction in short axis to \<10 mm or PR \[At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters\] as per RECIST version 1.1).
Time frame: Up to 4 years
Maximum Observed Plasma Concentration (Cmax) of Feladilimab-Part 1
Blood samples were collected at indicated time points for pharmacokinetic assessment.
Time frame: Pre-dose, end of infusion and 4 hours post dose at Day 1
Cmax of Tremelimumab-Part 1
Blood samples were collected at indicated time points for pharmacokinetic assessment.
Time frame: Pre-dose, end of infusion and 4 hours post dose at Day 1
Cmax of Feladilimab-Part 2
Blood samples were planned to be collected at indicated time points for pharmacokinetic assessment.
Time frame: Pre-dose at Weeks 1, 2, 4, 7, 10, 13, 16, 19, 25, then every 12 weeks for 2 years; end of infusion at Weeks 1, 19 and 25; and 4 hours post-infusion at Week 1
Cmax of Tremelimumab-Part 2
Blood samples were planned to be collected at indicated time points for pharmacokinetic assessment.
Time frame: Pre-dose at Weeks 1, 2, 4, 7, 10, 13, 16, 19, 25, then every 12 weeks for 2 years; end of infusion at Weeks 1, 19 and 25; and 4 hours post-infusion at Week 1
Minimum Observed Plasma Concentration (Cmin) of Feladilimab-Part 1
Blood samples were collected at indicated time points for pharmacokinetic assessment.
Time frame: Pre-dose, end of infusion and 4 hours post dose at Day 1
Cmin of Tremelimumab-Part 1
Blood samples were collected at indicated time points for pharmacokinetic assessment.
Time frame: Pre-dose, end of infusion and 4 hours post dose at Day 1
Cmin of Feladilimab-Part 2
Blood samples were planned to be collected at indicated time points for pharmacokinetic assessment.
Time frame: Pre-dose at Weeks 1, 2, 4, 7, 10, 13, 16, then every 12 weeks for 2 years; end of infusion; and 4 hours post-infusion at Week 1
Cmin of Tremelimumab-Part 2
Blood samples were planned to be collected at indicated time points for pharmacokinetic assessment.
Time frame: Pre-dose at Weeks 1, 2, 4, 7, 10, 13, 16, then every 12 weeks for 2 years; end of infusion; and 4 hours post-infusion at Week 1
Area Under the Plasma Concentration-time Curve (AUC[0-t]) of Feladilimab-Part 1
Blood samples were collected at indicated time points for pharmacokinetic assessment.
Time frame: Pre-dose, end of infusion and 4 hours post dose at Day 1
AUC(0-t) of Tremelimumab-Part 1
Blood samples were collected at indicated time points for pharmacokinetic assessment.
Time frame: Pre-dose, end of infusion and 4 hours post dose at Day 1
AUC(0-t) of Feladilimab-Part 2
Blood samples were planned to be collected at indicated time points for pharmacokinetic assessment.
Time frame: Pre-dose at Weeks 1, 2, 4, 7, 10, 13, 16, 19, 25, then every 12 weeks for 2 years; end of infusion at Weeks 1, 19 and 25, and 4 hours post-infusion at Week 1
AUC(0-t) of Tremelimumab-Part 2
Blood samples were planned to be collected at indicated time points for pharmacokinetic assessment
Time frame: Pre-dose at Weeks 1, 2, 4, 7, 10, 13, 16, then every 12 weeks for 2 years; end of infusion; and 4 hours post-infusion at Week 1
Number of Participants With Anti-drug Antibodies Against Feladilimab-Part 1
Serum samples were collected and tested for the presence of antibodies to feladilimab.
Time frame: Pre-dose at Week 4, 7, 10 and 13
Number of Participants With Anti-drug Antibodies Against Tremelimumab-Part 1
Serum samples were collected and tested for the presence of antibodies to tremelimumab.
Time frame: Pre-dose at Week 1, 4, 7, 10 and 13
Number of Participants With Anti-drug Antibodies Against Feladilimab-Part 2
Serum samples will be collected and tested for the presence of antibodies to feladilimab.
Time frame: Up to 2.5 years
Change From Baseline in Free T4-Part 2
Blood samples will be collected to assess change from baseline in free T4.
Time frame: Baseline and up to 2 years
Number of Participants With Anti-drug Antibodies Against Tremelimumab-Part 2
Serum samples will be collected and tested for the presence of antibodies to tremelimumab.
Time frame: Up to 2.5 years
Number of Participants With AEs, SAEs and AESI-Part 2
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is defined as any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent disability/incapacity; is a congenital anomaly/birth defect and important medical events may jeopardize the subject or may require medical or surgical intervention/SOC to prevent one of the other outcomes mentioned before. AESIs are defined as events of potential immunologic etiology, including immune related AEs.
Time frame: Up to 4 years
Number of Participants With AEs, SAEs, AESIs Based on Severity-Part 2
The severity of all toxicities were graded using the National Cancer Institute- Common Toxicity Criteria for Adverse Events (NCI-CTCAE) version 5.0. Grade 1: Mild reaction; infusion interruption not indicated; intervention not indicated; Grade 2: Requires therapy or infusion interruption but responds promptly to symptomatic treatment or prophylactic medications indicated for ≤24 hours; Grade 3: Prolonged (i.e., not rapidly responsive to symptomatic medication and/or brief interruption of infusion) or recurrence of symptoms following initial improvement; hospitalization indicated for other clinical sequelae; Grade 4: Life-threatening; pressor or ventilatory support indicated; Grade 5: Death related to AE
Time frame: Up to 4 years
Number of Participants With Severe- AEs/SAEs/DLTs Leading to Dose Modifications/Delays/Withdrawals-Part 2
The number of participants with severe- AE/SAE/DLTs leading to dose modifications/delays/withdrawals were planned to be summarized.
Time frame: Up to 4 years
Change From Baseline in SBP and DBP-Part 2
SBP and DBP will be measured after 5 minutes of rest for the participant.
Time frame: Baseline and up to 2 years
Change From Baseline in Temperature-Part 2
Temperature will be measured after 5 minutes of rest for the participant.
Time frame: Baseline and up to 2 years
Change From Baseline in Pulse Rate-Part 2
Pulse rate will be measured after 5 minutes of rest for the participant.
Time frame: Baseline and up to 2 years
Change From Baseline in Respiratory Rate-Part 2
Respiratory rate will be measured after 5 minutes of rest for the participant.
Time frame: Baseline and up to 2 years
Change From Baseline in Oxygen Saturation-Part 2
Oxygen saturation will be measured using pulse oximetry after 5 minutes of rest for the participant.
Time frame: Baseline and up to 2 years
Change From Baseline in ECG Measurement-Part 2
Single 12-lead ECG will be obtained using an automated ECG machine.
Time frame: Baseline (Pre-dose) up to 2 years
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count-Part 2
Blood samples will be collected to assess change from baseline in neutrophil, lymphocyte, monocyte, eosinophil, basophil and platelet count.
Time frame: Baseline and up to 2 years
Change From Baseline in Hemoglobin Level-Part 2
Blood samples will be collected to assess change from baseline in hemoglobin level.
Time frame: Baseline and up to 2 years
Change From Baseline in Hematocrit Level-Part 2
Blood samples will be collected to assess change from baseline in hematocrit level.
Time frame: Baseline and up to 2 years
Change From Baseline in Erythrocytes Count-Part 2
Blood samples will be collected to assess change from Baseline in erythrocytes count.
Time frame: Baseline and up to 2 years
Change From Baseline in Albumin and Total Protein Levels-Part 2
Blood samples will be collected to assess change from baseline in albumin and total protein levels.
Time frame: Baseline and up to 2 years
Change From Baseline in Creatinine and Bilirubin Levels-Part 2
Blood samples will be collected to assess change from baseline in creatinine and bilirubin levels.
Time frame: Baseline and up to 2 years
Change From Baseline in ALT, AST, ALP, LDH Levels-Part 2
Blood samples will be collected to assess change from baseline in ALT, AST ALP, LDH, amylase and lipase levels.
Time frame: Baseline and up to 2 years
Change From Baseline in Amylase and Lipase Levels-Part 2
Blood samples were collected to assess change from baseline in amylase and lipase levels.
Time frame: Baseline and up to 2 years
Change From Baseline in Urea, Glucose, Potassium, Sodium and Calcium Levels -Part 2
Blood samples will be collected to assess change in levels of urea, glucose, potassium, sodium and calcium from baseline.
Time frame: Baseline and up to 2 years
Change From Baseline in Specific Gravity of Urine-Part 2
Urine samples will be collected to assess change from Baseline in specific gravity of urine.
Time frame: Baseline and up to 2 years
Change From Baseline in pH of Urine-Part 2
Urine samples will be collected to assess change from baseline in pH of urine.
Time frame: Baseline and up to 2 years
Number of Participants With Abnormal Urinalysis Parameters-Part 2
The dipstick test gives positive or negative results for protein, ketones, occult blood and glucose. Positive test results were considered as abnormal. Number of participants with positive test results were planned to be summarized.
Time frame: Up to 2 years
Change From Baseline in TSH-Part 2
Blood samples will be collected to assess change from Baseline in TSH.
Time frame: Baseline and up to 2 years
Change From Baseline in Free T3-Part 2
Blood samples will be collected to assess change from baseline in free T3.
Time frame: Baseline and up to 2 years
The study was conducted in United States and Canada.
| Milestone | Part 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 75 mg | Part 1: Feladilimab 8 mg + Tremelimumab 225 mg | Part 1: Feladilimab 80 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 225 mg | Part 2: Feladilimab +Tremelimumab | Part 2: Standard of Care (SOC) |
|---|---|---|---|---|---|---|---|
| Started | 1 | 1 | 5 | 3 | 16 | 0 | 0 |
| Completed | 1 | 0 | 4 | 3 | 10 | 0 | 0 |
| Not completed | 0 | 1 | 1 | 0 | 6 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 | 2 | 0 | 0 |
| Withdrew: Study terminated by sponsor | 0 | 1 | 0 | 0 | 3 | 0 | 0 |
A DLT is considered by the investigator to be clinically relevant, attributed event within first 28 days of intervention meeting the following criteria of toxicity, Hematologic: Febrile neutropenia, Grade 4 neutropenia of greater than (\>) 7 days in duration or requiring Granulocyte- Colony stimulating factor (G-CSF), Grade 4 anemia and Grade 3 thrombocytopenia with bleeding or Grade 4 thrombocytopenia; Non-hematologic: Grade 4 toxicity, Grade 3 pneumonitis, any greater than or equal to (≥) Grade 2 pneumonitis that does not resolve to less than or equal to (≤ ) Grade 1 within 3 days of the initiation of maximal supportive care, Grade 3 toxicity that does not resolve to Grade 1 or baseline within 3 days despite optimal supportive care and any Grade 2 ocular toxicity requiring systemic steroids, or any ≥ Grade 3 ocular toxicity.
| Participants | Part 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 75 mg | Part 1: Feladilimab 8 mg + Tremelimumab 225 mg | Part 1: Feladilimab 80 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 225 mg |
|---|---|---|---|---|---|
| Number of Participants With Dose Limiting Toxicities (DLTs)-Part 1 | 0 | 0 | 0 | 0 | 1 |
The severity of all toxicities were graded using the National Cancer Institute- Common Toxicity Criteria for Adverse Events (NCI-CTCAE) version 5.0. Grade 1: Mild reaction; infusion interruption not indicated; intervention not indicated; Grade 2: Requires therapy or infusion interruption but responds promptly to symptomatic treatment or prophylactic medications indicated for ≤24 hours; Grade 3: Prolonged (i.e., not rapidly responsive to symptomatic medication and/or brief interruption of infusion) or recurrence of symptoms following initial improvement; hospitalization indicated for other clinical sequelae; Grade 4: Life-threatening; pressor or ventilatory support indicated; Grade 5: Death related to AE.
| Participants | Part 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 75 mg | Part 1: Feladilimab 8 mg + Tremelimumab 225 mg | Part 1: Feladilimab 80 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 225 mg |
|---|---|---|---|---|---|
| Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Grade 3 | 0 | 0 | 0 | 0 | 1 |
| Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Grade 5 | 0 | 0 | 0 | 0 | 0 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is defined as any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent disability/incapacity; is a congenital anomaly/birth defect and important medical events may jeopardize the subject or may require medical or surgical intervention/SOC to prevent one of the other outcomes mentioned before. AESIs are defined as events of potential immunologic etiology, including immune related AEs.
| Participants | Part 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 75 mg | Part 1: Feladilimab 8 mg + Tremelimumab 225 mg | Part 1: Feladilimab 80 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 225 mg |
|---|---|---|---|---|---|
| AEs | 1 | 1 | 5 | 3 | 16 |
| SAEs | 0 | 0 | 3 | 3 | 6 |
| AESIs | 0 | 0 | 2 | 0 | 7 |
The number of participants with AE/SAE/DLTs leading to dose modifications/delays/withdrawals were summarized.
| Participants | Part 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 75 mg | Part 1: Feladilimab 8 mg + Tremelimumab 225 mg | Part 1: Feladilimab 80 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 225 mg |
|---|---|---|---|---|---|
| Any Aes-Dose Modification | 0 | 0 | 0 | 0 | 0 |
| Any Aes-Dose Delay | 0 | 0 | 3 | 0 | 4 |
| Any Aes-Dose Withdrawal | 0 | 0 | 1 | 0 | 3 |
| Any SAEs-Dose Modification | 0 | 0 | 0 | 0 | 0 |
| Any SAEs-Dose Delay | 0 | 0 | 1 | 0 | 1 |
| Any SAEs-Dose Withdrawal | 0 | 0 | 1 | 0 | 2 |
| Any DLTs-Dose Modification | 0 | 0 | 0 | 0 | 0 |
| Any DLTs-Dose Delay | 0 | 0 | 0 | 0 | 1 |
| Any DLTs-Dose Withdrawal | 0 | 0 | 0 | 0 | 1 |
The severity of all toxicities were graded using the National Cancer Institute- Common Toxicity Criteria for Adverse Events (NCI-CTCAE) version 5.0. Grade 1: Mild reaction; infusion interruption not indicated; intervention not indicated; Grade 2: Requires therapy or infusion interruption but responds promptly to symptomatic treatment or prophylactic medications indicated for ≤24 hours; Grade 3: Prolonged (i.e., not rapidly responsive to symptomatic medication and/or brief interruption of infusion) or recurrence of symptoms following initial improvement; hospitalization indicated for other clinical sequelae; Grade 4: Life-threatening; pressor or ventilatory support indicated; Grade 5: Death related to AE.
| Participants | Part 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 75 mg | Part 1: Feladilimab 8 mg + Tremelimumab 225 mg | Part 1: Feladilimab 80 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 225 mg |
|---|---|---|---|---|---|
| Grade 1: AEs | 0 | 0 | 0 | 0 | 4 |
| Grade 2: AEs | 1 | 1 | 1 | 0 | 4 |
| Grade 3: AEs | 0 | 0 | 3 | 3 | 6 |
| Grade 4: AEs | 0 | 0 | 1 | 0 | 1 |
| Grade 5: AEs | 0 | 0 | 0 | 0 | 1 |
| Grade 1: SAEs | 0 | 0 | 0 | 0 | 0 |
| Grade 2: SAEs | 0 | 0 | 0 | 0 | 1 |
| Grade 3: SAEs | 0 | 0 | 2 | 3 | 3 |
| Grade 4: SAEs | 0 | 0 | 1 | 0 | 1 |
| Grade 5: SAEs | 0 | 0 | 0 | 0 | 1 |
| Grade 1: AESI | 0 | 0 | 0 | 0 | 3 |
| Grade 2: AESI | 0 | 0 | 2 | 0 | 2 |
| Grade 3: AESI | 0 | 0 | 0 | 0 | 1 |
| Grade 4: AESI | 0 | 0 | 0 | 0 | 1 |
| Grade 5: AESI | 0 | 0 | 0 | 0 | 0 |
The number of participants with severe- AE/SAE/DLTs leading to dose modifications/delays/withdrawals were summarized.
| Participants | Part 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 75 mg | Part 1: Feladilimab 8 mg + Tremelimumab 225 mg | Part 1: Feladilimab 80 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 225 mg |
|---|---|---|---|---|---|
| Any Severe Aes-Dose Modification | 0 | 0 | 0 | 0 | 0 |
| Any Severe Aes-Dose Delay | 0 | 0 | 3 | 0 | 4 |
| Any Severe Aes-Dose Withdrawal | 0 | 0 | 1 | 0 | 3 |
| Any Severe SAEs-Dose Modification | 0 | 0 | 0 | 0 | 0 |
| Any Severe SAEs-Dose Delay | 0 | 0 | 1 | 0 | 1 |
| Any Severe SAEs-Dose Withdrawal | 0 | 0 | 1 | 0 | 2 |
| Any Severe DLTs-Dose Modification | 0 | 0 | 0 | 0 | 0 |
| Any Severe DLTs-Dose Delay | 0 | 0 | 0 | 0 | 1 |
| Any Severe DLTs-Dose Withdrawal | 0 | 0 | 0 | 0 | 1 |
SBP and DBP were measured after 5 minutes of rest for the participant.
| Millimeters of mercury (mmHg) | Part 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 75 mg | Part 1: Feladilimab 8 mg + Tremelimumab 225 mg | Part 1: Feladilimab 80 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 225 mg |
|---|---|---|---|---|---|
| SBP, Baseline (Day 1) | 104 | 128 | 128 ± 14.967 | 133.67 ± 11.676 | 127.5 ± 16.415 |
| SBP, Week 4 | 16 | -12 | -10 ± 11.726 | -12 ± 11.533 | -0.27 ± 19.568 |
| DBP, Baseline (Day 1) | 73 | 79 | 83.4 ± 8.081 | 74.67 ± 4.041 | 76.25 ± 9.015 |
| DBP, Week 4 | 4 | -3 | -5 ± 3.162 | -4 ± 6.557 | -2.8 ± 7.552 |
Temperature was measured after 5 minutes of rest for the participant.
| Celsius (C) | Part 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 75 mg | Part 1: Feladilimab 8 mg + Tremelimumab 225 mg | Part 1: Feladilimab 80 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 225 mg |
|---|---|---|---|---|---|
| Baseline (Day 1) | 36.5 | 36.9 | 36.8 ± 0.212 | 36.6 ± 0.173 | 36.64 ± 0.479 |
| Week 4 | 0 | -0.3 | 0.04 ± 0.321 | 0.2 ± 0.1 | 0.04 ± 0.378 |
Pulse rate was measured after 5 minutes of rest for the participant.
| beats/minute | Part 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 75 mg | Part 1: Feladilimab 8 mg + Tremelimumab 225 mg | Part 1: Feladilimab 80 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 225 mg |
|---|---|---|---|---|---|
| Baseline (Day 1) | 81 | 83 | 91.6 ± 29.771 | 79.67 ± 9.074 | 76.56 ± 14.724 |
| Week 4 | 1 | 0 | -2.4 ± 20.732 | 5 ± 15.716 | 8.07 ± 10.747 |
Respiratory rate was measured after 5 minutes of rest for the participant.
| breaths/ minute | Part 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 75 mg | Part 1: Feladilimab 8 mg + Tremelimumab 225 mg | Part 1: Feladilimab 80 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 225 mg |
|---|---|---|---|---|---|
| Baseline (Day 1) | 18 | 18 | 17.6 ± 0.894 | 16 ± 0 | 16.75 ± 1.065 |
| Week 4 | 0 | -2 | 0 ± 1.414 | 2 ± 0 | 0.07 ± 1.668 |
Oxygen saturation was measured using pulse oximeter after 5 minutes of rest for the participant.
| Percentage (%) of Oxygen | Part 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 75 mg | Part 1: Feladilimab 8 mg + Tremelimumab 225 mg | Part 1: Feladilimab 80 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 225 mg |
|---|---|---|---|---|---|
| Baseline (Day 1) | 96 | 95 | 95.6 ± 2.881 | 96 ± 1.00 | 97.63 ± 1.586 |
| Week 4 | 2 | 5 | 0.8 ± 1.304 | 0 ± 2.00 | -0.2 ± 2.007 |
Single 12-lead ECG was obtained using an automated ECG machine. ECG findings were categorized as: normal, abnormal - clinically significant (CS), or abnormal - not clinically significant (NCS), as determined by the investigator.
| Participants | Part 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 75 mg | Part 1: Feladilimab 8 mg + Tremelimumab 225 mg | Part 1: Feladilimab 80 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 225 mg |
|---|---|---|---|---|---|
| Baseline (Pre dose, Day 1) — Normal | 1 | 1 | 1 | 1 | 6 |
| Baseline (Pre dose, Day 1) — Abnormal CS | 0 | 0 | 1 | 0 | 0 |
| Baseline (Pre dose, Day 1) — Abnormal NCS | 0 | 0 | 3 | 2 | 10 |
| Worst case Post-Baseline — Normal | 0 | 0 | 0 | 1 | 0 |
| Worst case Post-Baseline — Abnormal CS | 0 | 0 | 0 | 0 | 0 |
| Worst case Post-Baseline — Abnormal NCS | 0 | 0 | 0 | 1 | 2 |
Blood samples were collected to assess change from Baseline in neutrophil, lymphocyte, monocyte, eosinophil, basophil and platelet counts.
| 10^9 cells/liter | Part 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 75 mg | Part 1: Feladilimab 8 mg + Tremelimumab 225 mg | Part 1: Feladilimab 80 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 225 mg |
|---|---|---|---|---|---|
| Basophils, Baseline (Day 1) | 0.00 | 0.00 | 0.05 ± 0.0577 | 0.01 ± 0.0141 | 0.039 ± 0.048 |
| Basophils, Week 4 | 0.00 | — | 0 ± 0 | 0.005 ± 0.0071 | 0.007 ± 0.0344 |
| Eosinophils, Baseline (Day 1) | 0.3 | 0.1 | 0.35 ± 0.173 | 0.08 ± 0.113 | 0.2 ± 0.217 |
| Eosinophils, Week 4 | 0.4 | — | 0.03 ± 0.15 | 0.06 ± 0.064 | 0.07 ± 0.169 |
| Lymphocytes, Baseline (Day 1) | 1 | 1.5 | 0.9 ± 0.216 | 1.25 ± 0.212 | 0.92 ± 0.223 |
| Lymphocytes, Week 4 | 0.4 | — | 0.23 ± 0.15 | -0.38 ± 0.46 | 0.01 ± 0.185 |
| Monocytes, Baseline (Day 1) | 0.4 | 0.3 | 0.8 ± 0.2944 | 1.255 ± 0.9122 | 0.738 ± 0.3004 |
| Monocytes, Week 4 | 0 | — | 0.05 ± 0.1732 | -0.215 ± 0.1202 | 0.038 ± 0.2598 |
| Neutrophils, Baseline (Day 1) | 4 | 3.9 | 4.38 ± 1.548 | 6.2 ± 2.97 | 11.32 ± 21.379 |
| Neutrophils, Week 4 | 0.3 | — | 0.93 ± 0.512 | -0.9 ± 0.7 | -8.95 ± 26.151 |
| Platelets, Baseline (Day 1) | 196 | 325 | 250.6 ± 103.5 | 229.7 ± 147.06 | 266.3 ± 90.28 |
| Platelets, Week 4 | -1 | — | 8.6 ± 34.93 | -8.7 ± 16.65 | 31.3 ± 42.72 |
Blood samples were collected to assess change from baseline in hemoglobin level.
| grams/liter | Part 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 75 mg | Part 1: Feladilimab 8 mg + Tremelimumab 225 mg | Part 1: Feladilimab 80 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 225 mg |
|---|---|---|---|---|---|
| Baseline (Day 1) | 125 | 134 | 123.4 ± 32.61 | 125 ± 23.07 | 111.5 ± 12.74 |
| Week 4 | 5 | — | -5.8 ± 4.21 | 0.3 ± 2.89 | -0.7 ± 10.78 |
Blood samples were collected to assess change from baseline in hematocrit level.
| fraction of 1 | Part 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 75 mg | Part 1: Feladilimab 8 mg + Tremelimumab 225 mg | Part 1: Feladilimab 80 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 225 mg |
|---|---|---|---|---|---|
| Baseline (Day 1) | 0.38 | 0.4 | 0.385 ± 0.10999 | 0.3937 ± 0.0647 | 0.3421 ± 0.03603 |
| Week 4 | 0 | — | -0.0202 ± 0.01494 | -0.0017 ± 0.01102 | -0.0039 ± 0.03413 |
Blood samples were collected to assess change from baseline in Erythrocytes count.
| 10^12 cells/liter | Part 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 75 mg | Part 1: Feladilimab 8 mg + Tremelimumab 225 mg | Part 1: Feladilimab 80 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 225 mg |
|---|---|---|---|---|---|
| Baseline (Day 1) | 4.2 | 4.65 | 4.328 ± 1.2592 | 4.673 ± 0.4885 | 3.76 ± 0.526 |
| Week 4 | 0.13 | — | -0.216 ± 0.2131 | 0.04 ± 0.1652 | 0.016 ± 0.3913 |
Blood samples were collected to assess change from Baseline in albumin and total protein levels.
| grams/Liter | Part 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 75 mg | Part 1: Feladilimab 8 mg + Tremelimumab 225 mg | Part 1: Feladilimab 80 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 225 mg |
|---|---|---|---|---|---|
| Albumin, Baseline (Day 1) | 41 | 40 | 36 ± 7.18 | 36.7 ± 9.24 | 37.9 ± 2.79 |
| Albumin, Week 4 | 0 | — | 0 ± 3.81 | -0.7 ± 2.31 | -2.1 ± 2.81 |
| Protein, Baseline (Day 1) | 71 | — | 66.7 ± 7.02 | 73 ± 3.61 | 72.1 ± 6.51 |
| Protein, Week 4 | — | — | 3.3 ± 2.89 | 0 ± 4.36 | 1.4 ± 4.31 |
Blood samples were collected to assess change from baseline in creatinine and bilirubin levels.
| micromoles/ Liter | Part 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 75 mg | Part 1: Feladilimab 8 mg + Tremelimumab 225 mg | Part 1: Feladilimab 80 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 225 mg |
|---|---|---|---|---|---|
| Bilirubin, Baseline (Day 1) | 5 | 7 | 6.1 ± 2.44 | 6.1 ± 2.84 | 6.5 ± 4.23 |
| Bilirubin, Week 4 | -1 | — | 2.2 ± 2.48 | -1.1 ± 1.97 | -0.4 ± 1.52 |
| Creatinine, Baseline (Day 1) | 59000 | 63000 | 31636.7 ± 43702.44 | 73.5 ± 33.52 | 93 ± 44.72 |
| Creatinine, Week 4 | 1000 | — | -1798.9 ± 3493.56 | 3.1 ± 4.29 | -2.9 ± 9.53 |
Blood samples were collected to assess change from baseline in ALT, AST ALP, LDH levels.
| International Units/milliliter | Part 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 75 mg | Part 1: Feladilimab 8 mg + Tremelimumab 225 mg | Part 1: Feladilimab 80 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 225 mg |
|---|---|---|---|---|---|
| ALP, Baseline (Day 1) | 53 | 68 | 307.4 ± 416.93 | 121.5 ± 82.73 | 120.2 ± 60.54 |
| ALP, Week 4 | 2 | — | 55.8 ± 101.74 | -18 ± 25.46 | 36.2 ± 75.58 |
| ALT, Baseline (Day 1) | 18 | 25 | 24 ± 14.18 | 26.7 ± 24.79 | 18.2 ± 13.49 |
| ALT, Week 4 | -2 | — | 8.2 ± 13.05 | -4.7 ± 15.14 | 7.4 ± 26.46 |
| AST, Baseline (Day 1) | 32 | 44 | 24.6 ± 9.91 | 23.7 ± 15.89 | 21.9 ± 8.23 |
| AST, Week 4 | 0 | — | 10 ± 14.2 | -7 ± 14.73 | 12.9 ± 35.1 |
| LDH, Baseline (Day 1) | 325 | 382 | 228.8 ± 20.69 | 168 ± 104.23 | 239.9 ± 139.36 |
| LDH, Week 4 | 127 | — | 11.4 ± 42.76 | 31.3 ± 53.3 | 42.9 ± 85.66 |
Blood samples were collected to assess change from baseline in amylase and lipase levels.
| Units/milliliter | Part 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 75 mg | Part 1: Feladilimab 8 mg + Tremelimumab 225 mg | Part 1: Feladilimab 80 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 225 mg |
|---|---|---|---|---|---|
| Amylase, Baseline (Day 1) | 48 | 50 | 50.2 ± 34.85 | 40 ± 15.62 | 51.5 ± 26.72 |
| Amylase, Week 4 | -2 | — | -5.3 ± 7.23 | -5 ± 1 | -3.5 ± 9.64 |
| Lipase, Baseline (Day 1) | 28 | 23 | 50.8 ± 55.65 | 54.7 ± 48.99 | 34.6 ± 27.8 |
| Lipase, Week 4 | 0 | — | 1.5 ± 4.65 | -13 ± 23.81 | 6.1 ± 35.96 |
Blood samples were collected to assess change in levels of urea, glucose, potassium, sodium and calcium from baseline.
| millimoles/Liter | Part 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 75 mg | Part 1: Feladilimab 8 mg + Tremelimumab 225 mg | Part 1: Feladilimab 80 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 225 mg |
|---|---|---|---|---|---|
| Glucose, Baseline (Day 1) | 6.7 | 7.3 | 6.09 ± 1.6994 | 5.897 ± 0.2754 | 6.397 ± 1.5963 |
| Glucose, Week 4 | -0.3 | — | -0.365 ± 1.3225 | -0.848 ± 0.4949 | -0.11 ± 1.0164 |
| Calcium, Baseline (Day 1) | 2.37 | 2.24 | 2.325 ± 0.1221 | 2.397 ± 0.1475 | 2.33 ± 0.0886 |
| Calcium, Week 4 | 0.15 | — | 0.137 ± 0.1385 | 0.05 ± 0.1322 | -0.028 ± 0.0878 |
| Potassium, Baseline (Day 1) | 4.3 | 4 | 4.18 ± 0.606 | 4.3 ± 0.173 | 4.22 ± 0.391 |
| Potassium, Week 4 | -0.3 | — | 0.04 ± 0.586 | -0.03 ± 0.306 | -0.01 ± 0.328 |
| Sodium, Baseline (Day 1) | 138 | 140 | 137.2 ± 4.49 | 137.3 ± 3.21 | 137.1 ± 3.52 |
| Sodium, Week 4 | -1 | — | 0.2 ± 1.3 | 0.7 ± 0.58 | -1 ± 2.65 |
| Urea, Baseline (Day 1) | 3.4 | 3.3 | 6.36 ± 1.226 | 7.36 ± 0.75 | 6.92 ± 3.495 |
| Urea, Week 4 | 1.5 | — | -1.37 ± 1.09 | 1.08 ± 0.357 | -0.51 ± 1.633 |
Urine samples were collected to assess change from baseline in specific gravity of urine.
| Ratio | Part 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 75 mg | Part 1: Feladilimab 8 mg + Tremelimumab 225 mg | Part 1: Feladilimab 80 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 225 mg |
|---|---|---|---|---|---|
| Baseline (Day 1) | 1.015 | 1.02 | 1.0204 ± 0.00856 | 1.021 ± 0.01015 | 1.0159 ± 0.00605 |
| Week 4 | 0.005 | — | -0.0055 ± 0.00666 | 0.0013 ± 0.00115 | -0.0005 ± 0.006 |
Urine samples were collected to assess change from baseline in pH of urine.
| pH | Part 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 75 mg | Part 1: Feladilimab 8 mg + Tremelimumab 225 mg | Part 1: Feladilimab 80 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 225 mg |
|---|---|---|---|---|---|
| Baseline (Day 1) | 6.5 | 7 | 6 ± 1.173 | 5.33 ± 0.289 | 6.16 ± 0.826 |
| Week 4 | -0.5 | — | 0.5 ± 0.707 | -0.33 ± 0.289 | -0.24 ± 0.918 |
The dipstick test gives positive or negative results for protein, ketones, occult blood and glucose in urine. Positive test results were considered as abnormal. Number of participants with positive test results have been summarized.
| Participants | Part 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 75 mg | Part 1: Feladilimab 8 mg + Tremelimumab 225 mg | Part 1: Feladilimab 80 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 225 mg |
|---|---|---|---|---|---|
| Dip stick test for Glucose | 0 | — | 1 | 0 | 2 |
| Dip stick test for Protein | 0 | — | 1 | 0 | 6 |
| Dip stick test for Occult Blood | 1 | — | 2 | 1 | 5 |
| Dip stick test for Ketones | 0 | — | 4 | 0 | 3 |
Blood samples were collected to assess change from Baseline in TSH.
| milliUnits/Liter | Part 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 75 mg | Part 1: Feladilimab 8 mg + Tremelimumab 225 mg | Part 1: Feladilimab 80 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 225 mg |
|---|---|---|---|---|---|
| Baseline (Day 1) | 0.79 | 1.22 | 1.856 ± 1.6061 | 1.463 ± 1.2079 | 2.211 ± 1.7527 |
| Week 4 | — | — | — | -0.87 | — |
Blood samples were collected to assess change from Baseline in free T3.
| Picomoles per liter | Part 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 75 mg | Part 1: Feladilimab 8 mg + Tremelimumab 225 mg | Part 1: Feladilimab 80 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 225 mg |
|---|---|---|---|---|---|
| Baseline (Day 1) | 3.5 | 3.6 | 2.75 ± 0.212 | 4.47 | 3.88 ± 0.665 |
Blood samples were collected to assess change from baseline in free T4.
| Picomoles per liter | Part 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 75 mg | Part 1: Feladilimab 8 mg + Tremelimumab 225 mg | Part 1: Feladilimab 80 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 225 mg |
|---|---|---|---|---|---|
| Baseline (Day 1) | 10 | 11 | 12.43 ± 3.128 | 13.84 ± 2.296 | 15.98 ± 3.144 |
| Week 4 | — | — | — | 2.57 | — |
For participants in Part 2, overall survival is defined as time from the date of randomization to the date of death due to any cause.
No measurements were reported for this outcome.
Overall response rate is defined as percentage of participants with confirmed complete response (Disappearance of all target lesions. Any pathological lymph nodes \[whether target or non-target\] must have reduction in short axis to \<10 millimeter \[mm\]) or partial response (At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters) at any time as per response evaluation criteria in solid tumors (RECIST) version 1.1.
| Percentage of Participants | Part 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 75 mg | Part 1: Feladilimab 8 mg + Tremelimumab 225 mg | Part 1: Feladilimab 80 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 225 mg |
|---|---|---|---|---|---|
| Overall Response Rate-Part 1 | 0 (0 to 97.5) | 0 (0 to 97.5) | 0 (0 to 52.2) | 0 (0 to 70.8) | 6.3 (0.2 to 30.2) |
Overall response rate is defined as percentage of participants with confirmed complete response (Disappearance of all target lesions. Any pathological lymph nodes \[whether target or non-target\] must have reduction in short axis to \<10 mm) or partial response (At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters) at any time as per RECIST version 1.1.
No measurements were reported for this outcome.
Disease control rate is defined as percentage of subjects with confirmed complete response (Disappearance of all target lesions. Any pathological lymph nodes \[whether target or non-target\] must have reduction in short axis to \<10 mm) or partial response (At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters) or at least 18 weeks of stable disease (Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD) as per RECIST version 1.1.
| Percentage of Participants | Part 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 75 mg | Part 1: Feladilimab 8 mg + Tremelimumab 225 mg | Part 1: Feladilimab 80 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 225 mg |
|---|---|---|---|---|---|
| Disease Control Rate-Part 1 | 0 (0 to 97.5) | 0 (0 to 97.5) | 0 (0 to 52.2) | 33.3 (0.8 to 90.6) | 12.5 (1.6 to 38.3) |
Disease control rate is defined as percentage of subjects with confirmed complete response (Disappearance of all target lesions. Any pathological lymph nodes \[whether target or non-target\] must have reduction in short axis to \<10 mm) or partial response (At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters) or at least 18 weeks of stable disease (Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD) as per RECIST version 1.1.
No measurements were reported for this outcome.
For Part 2, progression free survival duration is defined as the time from the date of randomization to first documented evidence of disease progression (At least a 20% increase in the sum of diameters of target lesions and In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm) or death (regardless of cause of death), whichever comes first as per RECIST version 1.1.
No measurements were reported for this outcome.
Time to response is defined as the time from the first dose to the first documented evidence of complete response (Disappearance of all target lesions. Any pathological lymph nodes \[whether target or non-target\] must have reduction in short axis to \<10 mm) or partial response (At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters) for participants with a confirmed CR or PR as per RECIST version 1.1.
No measurements were reported for this outcome.
Duration of response is defined as time from the first documented evidence of response until the first documented sign of disease progression or death among participants who achieve a response (CR \[Disappearance of all target lesions. Any pathological lymph nodes {whether target or non-target} must have reduction in short axis to \<10 mm or PR \[At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters\] as per RECIST version 1.1).
No measurements were reported for this outcome.
Blood samples were collected at indicated time points for pharmacokinetic assessment.
| nanograms/milliliter | Part 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 75 mg | Part 1: Feladilimab 8 mg + Tremelimumab 225 mg | Part 1: Feladilimab 80 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 225 mg |
|---|---|---|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Feladilimab-Part 1 | 2758 | 5965 | 2686.6 ± 25.7 | 28340.9 ± 12.3 | 6098.3 ± 25.3 |
Blood samples were collected at indicated time points for pharmacokinetic assessment.
| nanograms/milliliter | Part 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 75 mg | Part 1: Feladilimab 8 mg + Tremelimumab 225 mg | Part 1: Feladilimab 80 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 225 mg |
|---|---|---|---|---|---|
| Cmax of Tremelimumab-Part 1 | 0 | 0 | 112312.1 ± 8.2 | — | 93206.7 ± 24.8 |
Blood samples were planned to be collected at indicated time points for pharmacokinetic assessment.
No measurements were reported for this outcome.
Blood samples were planned to be collected at indicated time points for pharmacokinetic assessment.
No measurements were reported for this outcome.
Blood samples were collected at indicated time points for pharmacokinetic assessment.
| nanograms/ milliliter | Part 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 75 mg | Part 1: Feladilimab 8 mg + Tremelimumab 225 mg | Part 1: Feladilimab 80 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 225 mg |
|---|---|---|---|---|---|
| Minimum Observed Plasma Concentration (Cmin) of Feladilimab-Part 1 | 462 | — | 348 ± 14.2 | 3197 ± 31 | 856.4 ± 35.9 |
Blood samples were collected at indicated time points for pharmacokinetic assessment.
| nanograms/ milliliter | Part 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 75 mg | Part 1: Feladilimab 8 mg + Tremelimumab 225 mg | Part 1: Feladilimab 80 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 225 mg |
|---|---|---|---|---|---|
| Cmin of Tremelimumab-Part 1 | 6467 | — | 22466.3 ± 58.4 | 5715.6 ± 43.9 | 15084.9 ± 48.4 |
Blood samples were planned to be collected at indicated time points for pharmacokinetic assessment.
No measurements were reported for this outcome.
Blood samples were planned to be collected at indicated time points for pharmacokinetic assessment.
No measurements were reported for this outcome.
Blood samples were collected at indicated time points for pharmacokinetic assessment.
| nanograms*hours/milliLiter | Part 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 75 mg | Part 1: Feladilimab 8 mg + Tremelimumab 225 mg | Part 1: Feladilimab 80 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 225 mg |
|---|---|---|---|---|---|
| Area Under the Plasma Concentration-time Curve (AUC[0-t]) of Feladilimab-Part 1 | 545097.4 | — | 453561.5 ± 11.7 | 4552653.1 ± 18.5 | 1055659.5 ± 23.5 |
Blood samples were collected at indicated time points for pharmacokinetic assessment.
| nanograms*hours/milliLiter | Part 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 75 mg | Part 1: Feladilimab 8 mg + Tremelimumab 225 mg | Part 1: Feladilimab 80 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 225 mg |
|---|---|---|---|---|---|
| AUC(0-t) of Tremelimumab-Part 1 | — | — | — | — | 18160725.7 ± 23.4 |
Blood samples were planned to be collected at indicated time points for pharmacokinetic assessment.
No measurements were reported for this outcome.
Blood samples were planned to be collected at indicated time points for pharmacokinetic assessment
No measurements were reported for this outcome.
Serum samples were collected and tested for the presence of antibodies to feladilimab.
| Participants | Part 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 75 mg | Part 1: Feladilimab 8 mg + Tremelimumab 225 mg | Part 1: Feladilimab 80 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 225 mg |
|---|---|---|---|---|---|
| Week 4 | 0 | 0 | 1 | 0 | 5 |
| Week 7 | 0 | 0 | 1 | 0 | 2 |
| Week 10 | 0 | 0 | 1 | 0 | 1 |
| Week 13 | 0 | 0 | 0 | 0 | 1 |
Serum samples were collected and tested for the presence of antibodies to tremelimumab.
| Participants | Part 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 75 mg | Part 1: Feladilimab 8 mg + Tremelimumab 225 mg | Part 1: Feladilimab 80 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 225 mg |
|---|---|---|---|---|---|
| Week 1 | 0 | 0 | 0 | 0 | 0 |
| Week 4 | 0 | 0 | 0 | 1 | 2 |
| Week 7 | 0 | 1 | 0 | 0 | 1 |
| Week 10 | 0 | 1 | 0 | 0 | 0 |
| Week 13 | 0 | 0 | 0 | 0 | 0 |
Serum samples will be collected and tested for the presence of antibodies to feladilimab.
No measurements were reported for this outcome.
Blood samples will be collected to assess change from baseline in free T4.
No measurements were reported for this outcome.
Serum samples will be collected and tested for the presence of antibodies to tremelimumab.
No measurements were reported for this outcome.
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is defined as any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent disability/incapacity; is a congenital anomaly/birth defect and important medical events may jeopardize the subject or may require medical or surgical intervention/SOC to prevent one of the other outcomes mentioned before. AESIs are defined as events of potential immunologic etiology, including immune related AEs.
No measurements were reported for this outcome.
The severity of all toxicities were graded using the National Cancer Institute- Common Toxicity Criteria for Adverse Events (NCI-CTCAE) version 5.0. Grade 1: Mild reaction; infusion interruption not indicated; intervention not indicated; Grade 2: Requires therapy or infusion interruption but responds promptly to symptomatic treatment or prophylactic medications indicated for ≤24 hours; Grade 3: Prolonged (i.e., not rapidly responsive to symptomatic medication and/or brief interruption of infusion) or recurrence of symptoms following initial improvement; hospitalization indicated for other clinical sequelae; Grade 4: Life-threatening; pressor or ventilatory support indicated; Grade 5: Death related to AE
No measurements were reported for this outcome.
The number of participants with severe- AE/SAE/DLTs leading to dose modifications/delays/withdrawals were planned to be summarized.
No measurements were reported for this outcome.
SBP and DBP will be measured after 5 minutes of rest for the participant.
No measurements were reported for this outcome.
Temperature will be measured after 5 minutes of rest for the participant.
No measurements were reported for this outcome.
Pulse rate will be measured after 5 minutes of rest for the participant.
No measurements were reported for this outcome.
Respiratory rate will be measured after 5 minutes of rest for the participant.
No measurements were reported for this outcome.
Oxygen saturation will be measured using pulse oximetry after 5 minutes of rest for the participant.
No measurements were reported for this outcome.
Single 12-lead ECG will be obtained using an automated ECG machine.
No measurements were reported for this outcome.
Blood samples will be collected to assess change from baseline in neutrophil, lymphocyte, monocyte, eosinophil, basophil and platelet count.
No measurements were reported for this outcome.
Blood samples will be collected to assess change from baseline in hemoglobin level.
No measurements were reported for this outcome.
Blood samples will be collected to assess change from baseline in hematocrit level.
No measurements were reported for this outcome.
Blood samples will be collected to assess change from Baseline in erythrocytes count.
No measurements were reported for this outcome.
Blood samples will be collected to assess change from baseline in albumin and total protein levels.
No measurements were reported for this outcome.
Blood samples will be collected to assess change from baseline in creatinine and bilirubin levels.
No measurements were reported for this outcome.
Blood samples will be collected to assess change from baseline in ALT, AST ALP, LDH, amylase and lipase levels.
No measurements were reported for this outcome.
Blood samples were collected to assess change from baseline in amylase and lipase levels.
No measurements were reported for this outcome.
Blood samples will be collected to assess change in levels of urea, glucose, potassium, sodium and calcium from baseline.
No measurements were reported for this outcome.
Urine samples will be collected to assess change from Baseline in specific gravity of urine.
No measurements were reported for this outcome.
Urine samples will be collected to assess change from baseline in pH of urine.
No measurements were reported for this outcome.
The dipstick test gives positive or negative results for protein, ketones, occult blood and glucose. Positive test results were considered as abnormal. Number of participants with positive test results were planned to be summarized.
No measurements were reported for this outcome.
Blood samples will be collected to assess change from Baseline in TSH.
No measurements were reported for this outcome.
Blood samples will be collected to assess change from baseline in free T3.
No measurements were reported for this outcome.
Collected over Non-serious adverse events (Non-SAEs) and serious adverse events (SAEs) were collected from Day 1 to upto 4 years. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mg | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| Part 1: Feladilimab 24 mg + Tremelimumab 75 mg | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| Part 1: Feladilimab 8 mg + Tremelimumab 225 mg | 0/5 (0%) | 3/5 (60%) | 5/5 (100%) |
| Part 1: Feladilimab 80 mg + Tremelimumab 75 mg | 0/3 (0%) | 3/3 (100%) | 3/3 (100%) |
| Part 1: Feladilimab 24 mg + Tremelimumab 225 mg | 1/16 (6.3%) | 6/16 (37.5%) | 16/16 (100%) |
| Part 2: Feladilimab + Tremelimumab | — | — | — |
| Part 2: Standard of Care (SOC) | — | — | — |
| Event | Part 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 75 mg | Part 1: Feladilimab 8 mg + Tremelimumab 225 mg | Part 1: Feladilimab 80 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 225 mg | Part 2: Feladilimab + Tremelimumab | Part 2: Standard of Care (SOC) |
|---|---|---|---|---|---|---|---|
| PneumoniaInfections and infestations | 0/1 | 0/1 | 0/5 | 1/3 | 0/16 | — | — |
| Bone painMusculoskeletal and connective tissue disorders | 0/1 | 0/1 | 0/5 | 1/3 | 0/16 | — | — |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 0/1 | 0/1 | 0/5 | 1/3 | 0/16 | — | — |
| EmbolismVascular disorders | 0/1 | 0/1 | 1/5 | 1/3 | 0/16 | — | — |
| Cardiac tamponadeCardiac disorders | 0/1 | 0/1 | 1/5 | 0/3 | 0/16 | — | — |
| BacteraemiaInfections and infestations | 0/1 | 0/1 | 1/5 | 0/3 | 0/16 | — | — |
| HyponatraemiaMetabolism and nutrition disorders | 0/1 | 0/1 | 1/5 | 0/3 | 0/16 | — | — |
| Pericardial effusion malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/1 | 0/1 | 1/5 | 0/3 | 0/16 | — | — |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/1 | 0/1 | 1/5 | 0/3 | 0/16 | — | — |
| ColitisGastrointestinal disorders | 0/1 | 0/1 | 0/5 | 0/3 | 1/16 | — | — |
| Event | Part 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 75 mg | Part 1: Feladilimab 8 mg + Tremelimumab 225 mg | Part 1: Feladilimab 80 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 225 mg | Part 2: Feladilimab + Tremelimumab | Part 2: Standard of Care (SOC) |
|---|---|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 1/1 | 0/1 | 1/5 | 0/3 | 8/16 | — | — |
| DyspepsiaGastrointestinal disorders | 1/1 | 0/1 | 1/5 | 0/3 | 0/16 | — | — |
| NauseaGastrointestinal disorders | 1/1 | 0/1 | 1/5 | 1/3 | 6/16 | — | — |
| Tumour painNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/1 | 0/1 | 0/5 | 0/3 | 1/16 | — | — |
| HaemothoraxRespiratory, thoracic and mediastinal disorders | 0/1 | 1/1 | 0/5 | 0/3 | 0/16 | — | — |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 0/1 | 1/1 | 0/5 | 0/3 | 0/16 | — | — |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/1 | 0/1 | 2/5 | 2/3 | 2/16 | — | — |
| FatigueGeneral disorders | 0/1 | 0/1 | 1/5 | 1/3 | 10/16 | — | — |
| AnaemiaBlood and lymphatic system disorders | 0/1 | 0/1 | 2/5 | 1/3 | 5/16 | — | — |
| Decreased appetiteMetabolism and nutrition disorders | 0/1 | 0/1 | 1/5 | 1/3 | 6/16 | — | — |
The sponsor made the decision to not continue the study at the end of Part 1 based on the totality of available data due to lack of efficacy and not due to safety. Hence Part 2 was not initiated and participants were not enrolled.
| Age, Continuous(YEARS) | Part 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 75 mg | Part 1: Feladilimab 8 mg + Tremelimumab 225 mg | Part 1: Feladilimab 80 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 225 mg | Part 2: Feladilimab + Tremelimumab | Part 2: Standard of Care (SOC) | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 51.0 ± 0 | 51.0 ± 0 | 58.2 ± 11.73 | 69.0 ± 12.77 | 66.8 ± 11.51 | — | — | 64.2 ± 11.95 |
| Sex: Female, Male(Participants) | Part 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 75 mg | Part 1: Feladilimab 8 mg + Tremelimumab 225 mg | Part 1: Feladilimab 80 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 225 mg | Part 2: Feladilimab + Tremelimumab | Part 2: Standard of Care (SOC) | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 1 | 1 | 3 | 0 | 4 | 0 | 0 | 9 |
| Male | 0 | 0 | 2 | 3 | 12 | 0 | 0 | 17 |
| Race/Ethnicity, Customized(Participants) | Part 1: Feladilimab (GSK3359609) 8 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 75 mg | Part 1: Feladilimab 8 mg + Tremelimumab 225 mg | Part 1: Feladilimab 80 mg + Tremelimumab 75 mg | Part 1: Feladilimab 24 mg + Tremelimumab 225 mg | Part 2: Feladilimab + Tremelimumab | Part 2: Standard of Care (SOC) | Total |
|---|---|---|---|---|---|---|---|---|
| Black or African American | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Multiple | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| White - White/Caucasian/European Heritage | 1 | 1 | 5 | 3 | 14 | 0 | 0 | 24 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — GSK will assess requests from qualified researchers for anonymized individual patient-level data (IPD) and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Anonymized IPD is made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
Data sharing details ↗ · www.gsk-studyregister.com
Ran from Nov 2018 to primary completion in Jun 2021, 30 months.
Results were first posted in Aug 2022, 1 year 1 month after primary completion.
Of 197 industry-sponsored phase 1/2 interventional studies under Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 88. This study's 30 months is below that.
Counting every sponsor, half of 299 studies reached it within 61 months; a quarter within 40 and three quarters within 89.
Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Feladilimab